Ryman rights trading ends on a sour note

Ryman rights trading ends on a sour note
Salt Funds' Matt Goodson said time will tell whether Ryman shares are cheap. (Image: Salt Funds)
Jenny Ruth
Ryman Healthcare’s $902 million rights issue is drawing to a dismal close, with the price of the rights falling as low as 7.5 cents on Tuesday, the last day of trading.Two weeks ago, in the institutional book-build auction process, institutional investors were prepared to pay an effective $1 for the rights.You could say that was a little disappointing because the theoretical value of the rights price was $1.03 – institutions paid $6 for the shares issued at $5, so the additional price paid reflected the value they put on the rights....

More Finance

‘Unusual’ volume of CCCFA changes in focus
Finance

‘Unusual’ volume of CCCFA changes in focus

Select committee mulls proposed changes to CCCFA, to report recommendations Oct 20.

Andy Macdonald 16 Sep 2025
Banks revise economic outlooks for Q2 GDP contraction
Finance

Banks revise economic outlooks for Q2 GDP contraction

Economists now see NZ's GDP contracting in Q2, but doubt a technical recession in Q3.

Andy Macdonald 15 Sep 2025
Real estate industry wants AML levy exemption
Finance

Real estate industry wants AML levy exemption

The real estate industry is warning an AML levy will drive up costs in the sector.

Michael Neilson 15 Sep 2025
Craigs' sweet spot for golden visa investors
Finance

Craigs' sweet spot for golden visa investors

Billionaires can go solo. For other wealthy investors, there's Craigs' new fund.